Soligenix (SNGX) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

SNGX Soligenix

Watchlist

3.3600
-0.1500-4.27%

Close Nov 21 16:00 ET

3.3501
-0.0099-0.29%

Post 16:13 ET

8.43MMarket Cap-522P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024
BenzingaNov 19 07:40 ET
Express News | Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
ReutersNov 19 07:30 ET
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels
BenzingaNov 14 07:15 ET
Express News | Soligenix Initiates a Phase 2 Clinical Trial of Sgx945 (Dusquetide) for the Treatment of Behçet's Disease
ReutersNov 14 07:15 ET
Express News | Soligenix Initiates A Phase 2 Clinical Trial Of SGX945 For The Treatment Of Behçet's Disease; Says Study DUS-AUBD-01 Opens Patient Enrollment
BenzingaNov 14 07:14 ET
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behçet's Disease
SoligenixNov 14 00:00 ET

Comments

Teddy123

Nov 20 04:46

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

$Soligenix (SNGX.US)$
19/11/2024 - 20:30
Phase 3 clinical study of HyBryte™ in CTCL initiating in 2024
PRINCETON, N.J., Nov. 19, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a European M...

Trytosaveabit

Nov 14 06:19

Update

$Soligenix (SNGX.US)$ On Thursday, Soligenix Inc. (NASDAQ:SNGX) opened patient enrollment for its DUS-AUBD-01 Phase 2 study evaluating SGX945 (dusquetide) for Behçet's Disease, an inflammatory disorder of the blood vessels (vasculitis).
The company looks forward to completing enrollment and announcing study results in the first half of 2025.
The pilot clinical trial of SGX945 will be an open-label study that will enroll approximately 25 patients aged 18 years or older with mild to moderate...

Jaguar8

Nov 14 06:16

NEWS

$Soligenix (SNGX.US)$
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
Soligenix (SNGX) has initiated patient enrollment for a Phase 2 clinical trial evaluating SGX945 (dusquetide) in treating Behçet's Disease.
The study received clearance from both FDA and Turkish authorities. The open-label trial will enroll approximately 25 patients with mild to moderate Behçet's Disease and active oral/genital ulcers.
Patients will receive twice-w...